Literature DB >> 19176870

Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer.

Geetika Chakravarty1, Alfredo A Santillan, Chad Galer, Henry P Adams, Abdal K El-Naggar, Samar A Jasser, Sayed Mohsin, Debasis Mondal, Gary L Clayman, Jeffrey N Myers.   

Abstract

Overexpression of insulin-like growth factor-I receptor (IGF-IR) is seen in a multitude of human thyroid cancers and correlates with poor prognosis. However, recent studies suggest that low phospho-IGF-IR (pIGF-IR) expression rather than its overexpression may be an indicator of poorly differentiated disease. No previous study has evaluated the expression of pIGF-IR to determine if activation or loss of expression of this receptor is associated with thyroid tumor progression. Accordingly, a quantitative immunohistochemical (IHC) method was used to evaluate the clinico-pathological significance of pIGF-IR expression in archival samples of human thyroid carcinomas. Quantitative analysis of pIGF-IR levels revealed a significant difference in the median index of pIGF-IR between different histological subtypes of thyroid cancer (P < 0.001). Specifically, the median pIGF-IR index of differentiated thyroid cancers was significantly higher than the median index of other poorly differentiated thyroid cancer (P < 0.001). This was further confirmed in individual tumor sections of thyroid carcinoma where anaplastic and differentiated components co-existed. No significant difference was noted in the pIGF-IR index of tumors grouped by size or stage but a trend towards lower mean pIGF-IR index was noted in older patients. Our data indicates that pIGF-IR is upregulated in a majority of follicular thyroid carcinomas, suggesting it may be a potential target for therapy for patients with this disease. In addition, since low pIGF-IR expression was found to correlate with aggressive human thyroid carcinoma, it also suggests that IGF-IR may not be needed for progression of anaplastic thyroid carcinoma possibly because other cell signaling pathways are activated, obviating the need for IGF-IR signaling. However, more mechanistic studies would be necessary to substantiate the possibility that pIGF-IR may be important for differentiation of thyroid tissues and is lost with disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19176870     DOI: 10.3181/0809-RM-284

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  7 in total

1.  Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.

Authors:  Elias Sozopoulos; Helen Litsiou; Gerassimos Voutsinas; Nikolaos Mitsiades; Nikolaos Anagnostakis; Thomais Tseva; Efstratios Patsouris; Sofia Tseleni-Balafouta
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

2.  Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas.

Authors:  Pei-Fang Wu; Wen-Chang Huang; James Chih-Hsin Yang; Yen-Shen Lu; Jin-Yuan Shih; Shang-Gin Wu; Ching-Hung Lin; Ann-Lii Cheng
Journal:  J Neurooncol       Date:  2013-07-02       Impact factor: 4.130

3.  The role of insulin-like growth factor 1 in the development of benign and malignant thyroid nodules.

Authors:  Engin Baştürk; Metin Kement; Dilek Yavuzer; Selahattin Vural; Cem Gezen; Hülya Ilıksu Gözü; Ayşe Karadayı; Mustafa Oncel
Journal:  Balkan Med J       Date:  2012-06-01       Impact factor: 2.021

Review 4.  IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review.

Authors:  Apostolos Karagiannis; Eva Kassi; Antonios Chatzigeorgiou; Michael Koutsilieris
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

5.  Advances in cellular therapy for the treatment of thyroid cancer.

Authors:  Claudia Papewalis; Margret Ehlers; Matthias Schott
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

Review 6.  Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?

Authors:  Roberta Malaguarnera; Veronica Vella; Maria Luisa Nicolosi; Antonino Belfiore
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-14       Impact factor: 5.555

Review 7.  Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer.

Authors:  Yevgeniya Kushchayeva; Sergiy Kushchayev; Kirk Jensen; Rebecca J Brown
Journal:  Cancers (Basel)       Date:  2022-01-22       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.